Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
PNL2 (Melanoma Associated Antigen) Antibody - With BSA and Azide
Mouse Monoclonal Antibody [Clone PNL2 ]
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| IHC, IF |
|---|---|
| Reactivity | Human, Mouse, Drosophila |
| Host | Mouse |
| Clonality | Monoclonal |
| Isotype | Mouse / IgG1 |
| Clone Names | PNL2 |
| Calculated MW | Multiple (160kDa, 100kDa and <10kDa) |
| Storage | Store at 2 to 8°C.Antibody is stable for 24 months. |
|---|---|
| Precautions | PNL2 (Melanoma Associated Antigen) Antibody - With BSA and Azide is for research use only and not for use in diagnostic or therapeutic procedures. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Anti-PNL2 is a novel monoclonal antibody, which has recently been introduced as an immunohistochemical reagent to stain melanocytes and tumors derived therefrom. The antigen recognized by PNL2 is different from Melan A and gp100. Its epitope is not destroyed by digestion with neuraminidase i.e. its epitope id not glycosylated. Anti-PNL2 may be most useful because of its high sensitivity for metastatic melanoma (87%), as opposed to 76% for anti-HMB45 and 82% for anti-MART-1. Anti-PNL2 labels intra-epidermal nevi while the dermal component of compound nevi are largely non-reactive with anti-PNL2. Antibodies against PNL2, MART-1 (Melan A) and HMB45 stain most clear cell sarcoma cells and a few cells in angio-myolipomas and lymphangioleiomyomatosis. Anti-PNL2 is a useful antibody for the identification of melanomas and clear cell sarcomas. Differential diagnosis is aided by the results from a panel of antibodies, including antibodies against HMB45, MART-1, tyrosinase, and MiTF.
References
Rochaix, P et al. PNL2, a New Monoclonal Antibody Directed against a Fixative-Resistant Melanocyte Antigen. Mod Pathol 2003;16(5):481-490. | J. A. Ramos-Vara and M. A. Miller. Immunohistochemical Identification of Canine Melanocytic Neoplasms With Antibodies to Melanocytic Antigen PNL2 and Tyrosinase: Comparison With Melan A. Veterinary Pathology OnlineFirst, published on September 21, 2010 as doi:10.1177/0300985810382095
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Shipping Information
